Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Cinzia Castellani"'
Autor:
Enrico Polati, Luca Dalle Carbonare, Alessandro Picelli, Katia Donadello, Vittorio Schweiger, Alvise Martini, Elena Mazzocchi, Maria Teresa Valenti, Erica Secchettin, Cinzia Castellani
Publikováno v:
Nutrients, Vol 12, Iss 3, p 821 (2020)
Nutrients
Volume 12
Issue 3
Nutrients
Volume 12
Issue 3
Objectives: Fibromyalgia syndrome (FMS) is a chronic clinical condition characterized by pain, fatigue, altered sleep, and cognitive disturbances. The purpose of this study was to compare two alternative treatments (nutraceutical and acupuncture) in
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Giuseppe Francia, Cinzia Castellani, Roberto Cerini, Lorenzo Trevisiol, Maria Vittoria Davì, Luca Dalle Carbonare, Elena Viva, Alessandro Zaccarella, Marcello Ferrari
Publikováno v:
Endocrine. 51:308-316
Pathogenesis and long-term outcome of obstructive sleep apnea syndrome (OSAS) in acromegalic patients are still under debate. The aim of the study was to assess the prevalence and long-term follow-up of a series of acromegalic patients with OSAS and
Autor:
Fabrizio Drudi, Maximilian Papi, Paola Tombesi, Cinzia Castellani, Federica Carloni, Davide Tassinari, Luigi Lazzari-Agli, Sergio Sartori
Publikováno v:
Oncology. 80:350-358
Background: To assess the efficacy and safety of bevacizumab-containing regimens in the treatment of advanced, chemotherapy-naive, non-squamous non-small cell lung cancer (NSCLC) on the basis of the two registrative trials [ECOG E4599 trial and BO177
Autor:
Paola Tombesi, Emanuela Scarpi, Cinzia Castellani, Fabrizio Drudi, Davide Tassinari, Federica Carloni, Sergio Sartori, Luigi Lazzari-Agli
Publikováno v:
American journal of clinical oncology. 35(6)
BACKGROUND To assess the role of the novel second-line treatments in nonsmall cell lung cancer (NSCLC). METHODS A systematic review of the literature with meta-analysis of phase III randomized clinical trials (RCTs) was independently performed by 3 a
Autor:
Davide, Tassinari, Fabrizio, Drudi, Federica, Carloni, Cinzia, Possenti, Carlotta, Santelmo, Cinzia, Castellani
Publikováno v:
Recenti progressi in medicina. 102(5)
Neuropathic pain is usually considered an "hard pain" both for the intrinsic difficulties in a correct diagnosis, and for the modest efficacy of the most part of conventional treatments. The most frequently used drugs in clinical practice are tricycl
Autor:
Cinzia Castellani, Fabrizio Drudi, M. Nicolini, Lorenzo Gianni, Manuela Fantini, Alberto Ravaioli, Carlotta Santelmo, Alessandra Affatato
Publikováno v:
Chemotherapy Research and Practice
The introduction of cisplatin in cancer treatment represents an important achievement in the oncologic field. Many types of cancers are now treated with this drug, and in testicular cancer patients major results are reached. Since 1965, other compoun
Autor:
Davide, Tassinari, Fabrizio, Drudi, Federica, Carloni, Cinzia, Castellani, Emanuela, Scarpi, Marco, Maltoni
Publikováno v:
Recenti progressi in medicina. 100(12)
Although oral morphine is the gold standard in the front-line approach to moderate-severe cancer pain, transdermal opiates are largely used in clinical practice. Aims of our work were to review the evidences of literature supporting these different h
Autor:
Fabrizio Drudi, Lorenzo Gianni, Manuela Fantini, Federica Carloni, Cinzia Castellani, Emiliano Tamburini, Davide Tassinari, Maximilian Papi, Alberto Ravaioli, Carlotta Santelmo
Publikováno v:
Journal of Clinical Oncology. 29:4042-4042
4042 Background: To assess the role of adjuvant treatments (AT; chemotherapy [AC] and/or chemo-radiotherapy [ACR]) in radically resected pancreatic cancer. Methods: A systematic review of literatur...
Autor:
Maximilian Papi, Emiliano Tamburini, Fabrizio Drudi, Carlotta Santelmo, Cinzia Castellani, Federica Carloni, E. Pasquini, Alberto Ravaioli, C. Possenti, Davide Tassinari
Publikováno v:
Journal of Clinical Oncology. 27:e19102-e19102
e19102 Background: To assess the role of a palliative treatment with gefitinib in advanced and heavily pre-treated NSCLC. Methods: The records of all the consecutive patients treated with G in our department were reviewed; all the patients pre-treate